Study summary · research use only
The role of mechano-growth factor E peptide in the regulation of osteosarcoma
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this in vitro study using osteosarcoma cell lines (species not specified), the effect of the mechano-growth factor E (MGF-E) peptide, derived from an IGF-I alternative splicing isoform, on osteosarcoma regulation was examined. The abstract reports that MGF was overexpressed in malignant osteosarcoma cells but not expressed in the least malignant cells, and that exogenous MGF-E treatment altered cell cycle distribution and increased proliferation, migration, and invasion of osteosarcoma cells. Mechanisms were investigated using quantitative polymerase chain reaction and western blotting. The authors state that MGF may be a candidate biomarker for malignant osteosarcoma phenotypes.
Abstract
Osteosarcoma is one of the most common bone tumors, and exhibits a high degree of malignancy. Gene therapy is a novel approach to its treatment, however, specific target genes are required to enable effective use of this therapy. In order to investigate the effects of the mechano-growth factor E (MGF-E) peptide, which is derived from the IGF-I alternative splicing isoform, on the regulation of the development of osteosarcoma, the expression of MGF was detected in osteosarcoma cell lines with different degrees of malignancy. Concomitantly, exogenous MGF-E peptide was used to stimulate these osteosarcoma cell lines. The results demonstrated that MGF was overexpressed in malignant osteosarcoma cells, while it was not expressed in the least malignant osteosarcoma cells. Furthermore, MGF-E treatment altered the cell cycle distribution, and promoted the proliferation, migration and invasion of osteosarcoma cells. The possible mechanisms underlying these effects were detected by quantitative polymerase chain reaction and western blotting. Based on these results, it was hypothesized that MGF may be a suitable biomarker for malignant osteosarcoma phenotypes.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.